| First Author | Al-Dhalimy M | Year | 2002 |
| Journal | Mol Genet Metab | Volume | 75 |
| Issue | 1 | Pages | 38-45 |
| PubMed ID | 11825062 | Mgi Jnum | J:74405 |
| Mgi Id | MGI:2158206 | Doi | 10.1006/mgme.2001.3266 |
| Citation | Al-Dhalimy M, et al. (2002) Long-Term Therapy with NTBC and Tyrosine-Restricted Diet in a Murine Model of Hereditary Tyrosinemia Type I. Mol Genet Metab 75(1):38-45 |
| abstractText | In human patients with hereditary tyrosinemia type I (HT1) a combination therapy of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3 cyclohexane dione (NTBC) and dietary restriction of phenylalanine and tyrosine is currently widely used. We previously reported that the use of NTBC in a murine model of HT1 abolished acute liver failure but did not prevent the development of hepatocellular carcinoma (HCC) in the setting of nonrestricted protein intake. Here we present the results obtained with higher doses of NTBC plus dietary tyrosine restriction on long-term follow up (>2 years). Liver function tests and succinylacetone levels were completely corrected with this regimen and cancer-free survival was improved when compared to historical controls. However, while no HT1 animals had HCC at age 13 months, the incidence was 2/16 (13%) at age 18 months and 1/6 (17%) after 24 months. Thus, even the most stringent therapy could not prevent the emergence of HCC in the mouse model of HT1, even when initiated prenatally. (C)2002 Elsevier Science (USA). |
